Regulatory Celcuity gains FDA approval for closely watched breast cancer drug BioPharma DiveStill, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk.OncologyRead full story pharminent July 15, 2026 (Last updated: July 20, 2026) BioPharma Dive Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: AAIC 2026: Anti-tau space begins to clarify as Biogen presents detailed data on antisense drugNext: J&J Streamlines Pharma Supply Chain Amid $55B US Manufacturing Push Related Stories Regulatory Celcuity gets FDA nod for first-in-class breast cancer drug pharminent July 15, 2026 Regulatory FDA clears at-home start dose for Alzheimer’s drug Leqembi pharminent July 14, 2026 Regulatory FDA posts new rejection letters days after confirming pause pharminent July 13, 2026
